StockpollyBeta
Get App
Popularity #3,327
ABOS · NASDAQ · Biotechnology

Acumen Pharmaceuticals (ABOS)

Develops sabirnetug, an investigational antibody for early symptomatic Alzheimer’s disease.

$2.67
vs last close+0.08 (+2.90%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
161818243240304227252133
Research & development111312202735253722211628
555555555555
Selling & marketing000000000000
General & administrative505555555555
Other expenses000000000000
Operating income−16−18−18−24−32−40−30−42−27−25−21−33
323432210000
Interest income344443222111
Interest expense011111111111
Other non-operating income0−3−4−5−4−3−3−2−1−1−1−1
Income before tax−13−16−15−21−30−37−29−41−26−25−21−33
Net income from continuing operations−13−16−15−21−30−37−29−41−26−25−21−33
Net income−13−16−15−21−30−37−29−41−26−25−21−33
EPS, basic−$0.24−$0.28−$0.25−$0.34−$0.50−$0.62−$0.48−$0.68−$0.44−$0.42−$0.33−$0.45
EPS, diluted−$0.24−$0.28−$0.25−$0.34−$0.50−$0.62−$0.48−$0.68−$0.44−$0.42−$0.33−$0.45
Weighted average shares, basic545860606060616161616372
Weighted average shares, diluted545860606060616161616372
EBITDA−16−16−14−19−29−36−28−40−25−24−20−31
Depreciation & amortization000000000000
EBIT−16−16−14−20−29−36−28−40−25−24−20−32